JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Evans, S. M.
Right arrow Articles by Griffiths, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Evans, S. M.
Right arrow Articles by Griffiths, R. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CAFFEINE

Vol. 289, Issue 1, 285-294, April 1999

Caffeine Withdrawal: A Parametric Analysis of Caffeine Dosing Conditions1

Suzette M. Evans2 and Roland R. Griffiths

Departments of Psychiatry and Behavioral Sciences (S.M.E., R.R.G.) and Neuroscience (R.R.G.), The Johns Hopkins University School of Medicine, Baltimore, Maryland

Although caffeine is the most widely used behaviorally active drug in the world, caffeine physical dependence has been only moderately well characterized in humans. Four double-blind experiments were conducted in independent groups of healthy participants to assess the conditions under which withdrawal symptoms occur upon cessation of low to moderate doses of caffeine. In experiment 1, there was no evidence that the range or magnitude of caffeine withdrawal symptoms differed when 300 mg of caffeine was consumed as a single dose in the morning versus 100 mg at three time points across the day. In experiment 2, both the range and severity of withdrawal increased as a function of caffeine maintenance dose (100, 300, and 600 mg/day), with even the lowest dose (100 mg) producing significant caffeine withdrawal. Experiment 3 showed that when individuals were maintained on 300 mg caffeine/day and tested with a range of lower doses (200, 100, 50, 25, and 0 mg/day), a substantial reduction in caffeine consumption (<= 100 mg/day) was necessary for the manifestation of caffeine withdrawal. Experiment 4 manipulated duration of exposure to caffeine (1, 3, 7, or 14 days of 300 mg/day) and showed that caffeine withdrawal occurred after as little as 3 days of caffeine exposure, with a somewhat increased severity of withdrawal observed after 7 or 14 days of exposure. As a whole, this set of experiments provides the most complete parametric characterization of caffeine withdrawal to date and suggests that caffeine physical dependence can occur under more modest conditions (i.e., fewer doses per day, lower daily dose, shorter duration of exposure) than previously recognized.


0022-3565/99/2891-0285$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Br. J. Sports. Med.Home page
A. Bassini-Cameron, E. Sweet, A. Bottino, C. Bittar, C. Veiga, L.-C. Cameron, and E. H M Dantas
Effect of caffeine supplementation on haematological and biochemical variables in elite soccer players under physical stress conditions * COMMENTARY
Br. J. Sports Med., August 1, 2007; 41(8): 523 - 530.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
C. F. Haskell, D. O. Kennedy, K. A. Wesnes, A. L. Milne, and A. B. Scholey
A double-blind, placebo-controlled, multi-dose evaluation of the acute behavioural effects of guarana in humans
J Psychopharmacol, January 1, 2007; 21(1): 65 - 70.
[Abstract] [PDF]


Home page
Psychosom. Med.Home page
W. R. Lovallo, T. L. Whitsett, M. al'Absi, B. H. Sung, A. S. Vincent, and M. F. Wilson
Caffeine Stimulation of Cortisol Secretion Across the Waking Hours in Relation to Caffeine Intake Levels
Psychosom Med, September 1, 2005; 67(5): 734 - 739.
[Abstract] [Full Text] [PDF]


Home page
Psychosom. Med.Home page
J. E. James
Critical Review of Dietary Caffeine and Blood Pressure: A Relationship That Should Be Taken More Seriously
Psychosom Med, January 1, 2004; 66(1): 63 - 71.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
I. Biaggioni and S. N. Davis
Caffeine: A Cause of Insulin Resistance?
Diabetes Care, February 1, 2002; 25(2): 399 - 400.
[Full Text] [PDF]


Home page
Arch Fam MedHome page
R. R. Griffiths and E. M. Vernotica
Is Caffeine a Flavoring Agent in Cola Soft Drinks?
Arch Fam Med, August 1, 2000; 9(8): 727 - 734.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.